FdaApplication
BLA 761085
Identifiers
- fda_app_no: BLA761085
Properties
| Property | Value |
|---|---|
| applicant_name | Evolus Inc. |
| application_type | BLA |
| approval_date | 2019-02-01 |
Revenue by product
JEUVEAU
| Period | Revenue |
|---|---|
| Q2 2026 | $74.5M |
| Q1 2026 | $66.0M |
| Q4 2025 | $82.0M |
| Q3 2025 | $63.2M |
| Q2 2025 | $59.0M |
| Q1 2025 | $68.1M |
| Q4 2024 | $79.0M |
| Q3 2024 | $60.2M |
| Q2 2024 | $66.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| JEUVEAU | PRABOTULINUMTOXINA-XVFS | 100UNITS | For Injection |
1 product